RESUMO
Objective To investigate the effect of Kangxin Capsule on the stability of atherosclerotic plaque in rabbits. Methods Forty purebred male New Zealand white rabbits were randomly divided into model group, atorvastatin group, Kangxin Capsule high and low dose groups, and normal control group, 8 rabbit for each group, and were given corresponding administration. Atherosclerosis model was made by intimal injury and high cholesterol diet except for normal control group. After 6 W, aortic vascular pathomorphology were observed, and immunohistochemical method was used to detect the expression of MMP-2 and VCAM-1 in atherosclerotic plaques. Results Compared with model group, the ratio of the thickness of wall to the area of lumina (W/L), average optical density, and the percentage of positive area of Kangxin Capsule groups were less, also, the expression of MMP-2 and VCAM-1 were reduced. The differences were significant (P<0.05 or P<0.01), especially in the high-dose group. Conclusion Kangxin Capsule can reduce the expression of MMP-2 and VCAM-1, which is the possible mechanism of stabilizing the atherosclerotic plaque.
RESUMO
Objective To discuss the influence of Yifei-Kangxin capsule on MMP-1 in Wistar rats model with pulmonary heart disease. Methods 40 Wistar rats with pulmonary heart disease were averagely grouped as Normal Group, Model Group, Therapeutic Group and Comparative Group randomly by weight. The rats in Therapeutic Group were given Yifei-Kangxin capsule and the rats in Comparative Group were given Nifedipine. The course of treatment was 15 days. The rats were killed at the next 7th, 14th and 28th day separately to test MMP-1 in pulmonary tissue. Results After the treatment, the expression of MMP-1 in pulmonary tissue of the Therapeutic Group[7 d, 14 d, 28 d was(0.231±0.017)ng/m、(0.308±0.081)ng/m、(0.358±0.074)ng/m]was lower than the Model Group[7 d, 14 d, 28 d was(0.266±0.036)ng/m 、(0.315± 0.060)ng/m、(0.612±0.091)ng/m]. Conclusion Yifei-Kangxin capsule can inhibit the expression of MMP-1 in the rats model pulmonary heart disease.